Novartis AG
BIOMARKERS AND CAR T CELL THERAPIES WITH ENHANCED EFFICACY

Abstract:

The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with altered expression and/or function of one or more genes, e.g., associated with Tet2, and methods of use therefore. The invention further provides inhibitors of the one or more genes and methods of use therefore in connection with CAR T cells.